In addition, the results uncovered that the expression of ADAM17 was positively correlated with an immunostimulator (IL6R) (Figure 7B) and immunoinhibitors (CD274, KDR, TGFBR1) (Figure 7C) in most cancer types. Here, ADAM17 is linked to cancer.